The House Oversight Committee quietly announced that it would hold a hearing on controversial drug pricing practices amid intensifying criticism from Democrats.
A spokeswoman for Chairman Jason Chaffetz (R-Utah) said in a statement that he plans to hold a hearing “early next year.”
Chaffetz has been under fierce pressure from the committee’s 18 Democrats, led by Ranking Member Elijah Cummings (D-Md.), to investigate the aggressive drug pricing by companies like Turing and Valeant pharmaceuticals.
Read Full Article »